Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 10;28(7):1302–1312. doi: 10.1158/1078-0432.CCR-21-3597

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 1. Responses and time on entrectinib treatment in patients with NTRK fusion-positive solid tumors, by tumor type (BICR assessed). A, Best individual patient responses [n = 103; 18 patients with missing sum of the longest diameter (SLD) change were excluded from the plot]. B, Time on entrectinib treatment. Data cut-off August 31, 2020. The minimum shrinkage in the SLD of target lesions that defined an OR was 30%. Gastrointestinal (GI)-other, adenocarcinoma of upper GI tract; CRC, colorectal carcinoma; CUP, cancer of unknown primary; Inv, investigator; ND, not determined; SD, stable disease. — Responses and time on entrectinib treatment in patients with NTRK fusion-positive solid tumors, by tumor type (BICR assessed). A, Best individual patient responses [n = 103; 18 patients with missing sum of the longest diameter (SLD) change were excluded from the plot]. B, Time on entrectinib treatment. Data cut-off August 31, 2020. The minimum shrinkage in the SLD of target lesions that defined an OR was 30%. Gastrointestinal (GI)-other, adenocarcinoma of upper GI tract; CRC, colorectal carcinoma; CUP, cancer of unknown primary; Inv, investigator; ND, not determined; SD, stable disease.